PMID- 35911715 OWN - NLM STAT- MEDLINE DCOM- 20220802 LR - 20221207 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 13 DP - 2022 TI - Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies. PG - 882172 LID - 10.3389/fimmu.2022.882172 [doi] LID - 882172 AB - PURPOSE: This study determined the efficacy of low-dose gemcitabine combined with programmed death-1 (PD-1) inhibitors for treating multiple malignancies, providing a cost-effective and safe treatment option. STUDY DESIGN: This study included 61 patients with advanced solid tumors treated with low-dose gemcitabine combined with PD-1 inhibitors at the Henan Cancer Hospital between January 2018 and February 2022. We retrospectively reviewed medical records to evaluate several clinical factors, including progression-free survival (PFS), overall survival (OS), adverse effects (AEs), and objective response to treatment. RESULTS: Sixty-one patients received treatment with low-dose gemcitabine combined with PD-1 inhibitors. The objective response rate (ORR) was 29.5% and the disease control rate (DCR) was 62.3%. The median PFS was 4.3 months (95% confidence interval, 2.3 to 6.3 months) and the median OS was 15.0 months (95% confidence interval, 8.8 to 21.2 months). Hematological toxicity, mainly leukopenia or thrombocytopenia, was the most common AE, with any-grade and grade 3/4 hematological toxicity reported in 60.7 and 13.1% of patients, respectively. CONCLUSIONS: Low-dose gemcitabine combined with PD-1 inhibitors may offer a novel treatment option for patients with advanced malignancies. CI - Copyright (c) 2022 Huang, Peng, Zhang, Till, Yang, Zhang, Zhao, Fu, Li, Han, Qin, Chen, Yan, Liu, Wang, Ye, Li, Gao and Wang. FAU - Huang, Hao AU - Huang H AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Peng, Ling AU - Peng L AD - Department of Respiratory Disease, Zhejiang Provincial People's Hospital, Hangzhou, China. FAU - Zhang, Bicheng AU - Zhang B AD - Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China. FAU - Till, Brian G AU - Till BG AD - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. FAU - Yang, Yonghao AU - Yang Y AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Zhang, Xiaojie AU - Zhang X AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Zhao, Lingdi AU - Zhao L AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Fu, Xiaomin AU - Fu X AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Li, Tiepeng AU - Li T AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Han, Lu AU - Han L AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Qin, Peng AU - Qin P AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Chen, Lin AU - Chen L AD - Guangzhou Medical University-Guangzhou Institute of Biomedicine and Health GZMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China. FAU - Yan, Xiang AU - Yan X AD - Medical Oncology Department, Chinese People's Liberation Army PLA General Hospital, Beijing, China. FAU - Liu, Yang AU - Liu Y AD - Department of Radiotherapy, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. FAU - Wang, Wenkang AU - Wang W AD - Department of Breast Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. FAU - Ye, Zhenlong AU - Ye Z AD - Mengchao Cancer Hospital, Shanghai University, Shanghai, China. AD - Department of Immune Cell Research, Shanghai Engineering Research Center for Cell Therapy, Shanghai, China. AD - School of Pharmacy, Binzhou Medical University, Binzhou, China. FAU - Li, Hongle AU - Li H AD - Molecular Pathology Department, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China. FAU - Gao, Quanli AU - Gao Q AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. FAU - Wang, Zibing AU - Wang Z AD - Department of Immunotherapy, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220713 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Immune Checkpoint Inhibitors) RN - 0W860991D6 (Deoxycytidine) RN - 0 (Gemcitabine) SB - IM MH - Deoxycytidine/adverse effects/analogs & derivatives MH - Humans MH - *Immune Checkpoint Inhibitors MH - *Neoplasms/chemically induced/drug therapy MH - Retrospective Studies MH - Gemcitabine PMC - PMC9328170 OTO - NOTNLM OT - PD-1 inhibitors OT - combination immunotherapy OT - gemcitabine OT - low-dose chemotherapy OT - malignancy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/08/02 06:00 MHDA- 2022/08/03 06:00 PMCR- 2022/01/01 CRDT- 2022/08/01 03:50 PHST- 2022/02/23 00:00 [received] PHST- 2022/06/03 00:00 [accepted] PHST- 2022/08/01 03:50 [entrez] PHST- 2022/08/02 06:00 [pubmed] PHST- 2022/08/03 06:00 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2022.882172 [doi] PST - epublish SO - Front Immunol. 2022 Jul 13;13:882172. doi: 10.3389/fimmu.2022.882172. eCollection 2022.